St. Jude Children's Research Hospital

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1962-01-01

Employees: -

Market Cap: -

Website: http://www.stjude.org/

Clinical Trials

Trial of Antibody Responses by Vitamin Supplementation

Phase 1

Recruiting

Conditions: Healthy Participants

Interventions: Biological: No vitamin A supplementation
Biological: Vitamin A supplementation

First Posted Date: 2019-03-01

Last Posted Date: 2024-02-07

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 80

Registration Number: NCT03859687

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies

Phase 2

Active, not recruiting

Conditions: Hodgkin Lymphoma
Acute Lymphoblastic Leukemia (ALL)
Acute Myeloid Leukemia (AML)
Myelodysplastic Syndromes (MDS)
NK-Cell Leukemia
Non Hodgkin Lymphoma (NHL)
Juvenile Myelomonocytic Leukemia (JMML)
Chronic Myeloid Leukemia (CML)

Interventions: Drug: Cyclophosphamide
Biological: Fludarabine
Drug: Thiotepa
Drug: Melphalan
Biological: G-csf
Drug: Mesna
Device: CliniMACS
Biological: ATG (rabbit)
Drug: Blinatumomab
Biological: TCRα/β+
Biological: CD19+
Biological: CD45RA-depleted DLI

First Posted Date: 2019-02-21

Last Posted Date: 2024-08-19

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 140

Registration Number: NCT03849651

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Feasibility and Agreement of Remote Evaluation of Resting Heart Rate and Heart Rate Variability in Survivors of Hodgkin Lymphoma Treated With Chest Radiation (PILOT STUDY-SURVIVOR)

Completed

Conditions: Hodgkin Disease

First Posted Date: 2019-02-12

Last Posted Date: 2024-08-09

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 34

Registration Number: NCT03838627

Locations: 🇺🇸
Kirsten Ness, Memphis, Tennessee, United States

Hydroxyurea Therapy: Optimizing Access in Pediatric Populations Everywhere

Phase 2

Terminated

Conditions: Sickle Cell Disease
Thalassemia

Interventions: Drug: Hydroxyurea Oral Capsule
Drug: Hydroxyurea

First Posted Date: 2019-01-31

Last Posted Date: 2022-03-18

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 1

Registration Number: NCT03825341

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17

Phase 2

Recruiting

Conditions: Hodgkin Lymphoma

Interventions: Drug: bendamustine
Drug: Etoposide
Drug: Doxorubicin
Drug: Bleomycin
Drug: Vincristine
Drug: Brentuximab Vedotin
Drug: Vinblastine
Drug: Cyclophosphamide
Drug: Prednisone
Drug: DTIC
Drug: Filgrastim
Other: Quality of Life Measurements
Radiation: Radiotherapy

First Posted Date: 2018-11-28

Last Posted Date: 2024-04-04

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 250

Registration Number: NCT03755804

Locations: 🇺🇸
Maine Children's Cancer Program, Scarborough, Maine, United States
🇺🇸
St. Jude Affiliate Baton Rouge Clinic (Our Lady of the Lakes Regional Medical Center), Baton Rouge, Louisiana, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

and more 5 locations

Antibiotic Resistance in Global Pediatric Oncology Centers

Completed

Conditions: Antibiotic Resistant Infection

First Posted Date: 2018-10-26

Last Posted Date: 2022-08-03

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 560

Registration Number: NCT03721562

Locations: 🇸🇻
Hospital Nacional de Niños Benjamín Bloom, San Salvador, El Salvador
🇬🇹
Unidad Nacional de Oncología Pediátrica, Guatemala, Guatemala
🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

and more 2 locations

Exploring Adherence Monitoring in Sickle Cell Disease

Active, not recruiting

Conditions: Sickle Cell Disease

First Posted Date: 2018-10-17

Last Posted Date: 2024-05-07

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 45

Registration Number: NCT03708731

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Study of GDC-0084 in Pediatric Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma or Diffuse Midline Gliomas

Phase 1

Completed

Conditions: Brain and Central Nervous System Tumors

Interventions: Drug: GDC-0084
Radiation: radiation therapy

First Posted Date: 2018-10-04

Last Posted Date: 2023-01-18

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 27

Registration Number: NCT03696355

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Haplocompatible Transplant Using TCRα/β Depletion Followed by CD45RA-Depleted Donor Lymphocyte Infusions for Severe Combined Immunodeficiency (SCID)

Phase 1

Active, not recruiting

Conditions: Severe Combined Immunodeficiency

Interventions: Drug: Anti-thymocyte globulin (rabbit)
Drug: Busulfan
Other: Donor Lymphocyte Infusion
Drug: Fludarabine
Drug: Thiotepa
Device: CliniMACS

First Posted Date: 2018-07-24

Last Posted Date: 2024-06-12

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 4

Registration Number: NCT03597594

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Postural Control Under Different Cognitive Loads in Adult Survivors of Acute Lymphoblastic Leukemia and Age-Matched Healthy Individuals

Completed

Conditions: Acute Lymphoblastic Leukemia

First Posted Date: 2018-07-10

Last Posted Date: 2022-09-19

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 92

Registration Number: NCT03581045

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy